logo-loader
viewImugene Ltd

Imugene to present new data from HER-Vaxx cancer vaccine phase 1b trial

Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor.

cancer cells
Phase 1b HER-Vaxx study has met all its primary endpoints

Imugene Ltd (ASX:IMU) will present the updated patient data from its phase 1b study of HER-Vaxx cancer vaccine at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

The abstract will be presented by Dr Yee Chao, director of the Department of Oncology at the Veterans General Hospital in Taipei, Taiwan and a lead investigator in the phase 1b study.

Dr Chao’s presentation will be featured at the ASCO Gastrointestinal (Non-colorectal) Cancer Session on Monday June 3, 2019 between 8:00 am and 11:00 am.

READ: Imugene well-funded to progress clinical milestones

It is worth noting that Imugene’s phase 1b HER-Vaxx study which completed enrolment in 2018 has met all its primary endpoints.

The study is ongoing with patients continuing to receive HER-Vaxx every 3 months to maintain high levels of cancer targeting antibodies. A phase 2 study was initiated in March 2019.

ASCO presentation

Imugene’s ASCO presentation is entitled: ‘A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.’

The ASCO annual meeting attracts more than 40,000 cancer specialists and is one of the largest educational and scientific events in the oncology community where the latest research and clinical results are highlighted.

Imugene managing director and chief executive officer Leslie Chong said: “There is continued interest in the positive data from our Phase 1b trial which clearly supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.”

 

Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu.

It has been shown in pre-clinical studies and now in phase I studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Quick facts: Imugene Ltd

Price: 0.021 AUD

ASX:IMU
Market: ASX
Market Cap: $75.81 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development...

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine.   The company had a pre-investigational new drug meeting with the US Food and Drug Administration...

on 20/3/19

2 min read